Clinical Trials Logo

Clinical Trial Summary

Ischemic bowel disease, also known as ischemic bowel disease (IBD), is a type of disease that causes the blood supply to a certain intestinal segment to be reduced or stopped by various reasons such as hypovolemia, shock or recent abdominal surgery, resulting in insufficient blood supply to the intestinal wall, and causing a series of pathological changes in the intestine. Human umbilical cord blood mononuclear cells (HUCB-MNC) can be economically and conveniently isolated from human cord blood. The HUCB-MNC obtained from the isolation of human umbilical cord blood contains a variety of stem cells, such as hematopoietic stem cells, endothelial stem cells, etc. A number of previous studies have confirmed that HUCB-MNC can improve the occurrence of ischemic bowel disease through immunomodulatory and tissue repair. These characteristics make HUCB-MNC a cell with great potential to treat ischemic diseases.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05560672
Study type Interventional
Source Qianfoshan Hospital
Contact HongLi HL Yang, Dr
Phone 13791123806
Email 13791123806@163.com
Status Recruiting
Phase N/A
Start date September 1, 2019
Completion date September 1, 2024